Postmenopausal hormone therapy: Impact on menopause-related symptoms, chronic disease and quality of life

Drugs

Volumn 64, Issue 8, 2004, Pages 821-836

  Van Der Mooren, Marius Jan ^a,b   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CLONIDINE; DIURETIC AGENT; ESTRADIOL; ESTRIOL SUCCINATE; ESTROGEN; FLUOXETINE; FOLIC ACID; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; PHOSPHONIC ACID DERIVATIVE; PHYTOESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; VENLAFAXINE; VITAMIN D;

AGITATION; ALZHEIMER DISEASE; AMNESIA; ANXIETY; ARTHRALGIA; BREAST CANCER; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLIMACTERIUM; CLINICAL TRIAL; COLORECTAL CANCER; CUTANEOUS PARAMETERS; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DYSURIA; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; EXERCISE; FEMALE SEXUAL DYSFUNCTION; FLUID RETENTION; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; HEADACHE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; IRRITABILITY; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MENOPAUSE RELATED DISORDER; META ANALYSIS; MOOD DISORDER; MYALGIA; NAUSEA; NERVOUSNESS; NOCTURIA; NOSE MUCOSA; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; OVARY CANCER; PATIENT COUNSELING; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN IRRITATION; STROKE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WELLBEING;

CHRONIC DISEASE; DRUG THERAPY, COMBINATION; ESTROGENS; HORMONES; HUMANS; MENOPAUSE; POSTMENOPAUSE; PROGESTINS; QUALITY OF LIFE;

EID: 2342520648     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464080-00003     Document Type: Review

References (138)

1. Kenemans P, Barentsen R, van de Weijer PHM. Practical HRT. 2nd rev. ed. Zeist, The Netherlands: Medical Forum, 1996
2. Eskin BA. The menopause: comprehensive management. 4th ed. New York: Parthenon Publishing Group, 2000
3. Greene JG, Cooke DJ. Life stress and symptoms at the climacterium. Br J Psychiatry 1980; 136: 486-91
4. Glazer G, Zeller R, Delumba L, et al. The Ohio Midlife Women's Study. Health Care Women Int 2002; 23: 612-30
5. Bosworth HB, Bastian LA, Rimer BK, et al. Coping styles and personality domains related to menopausal stress. Womens Health Issues 2003; 13: 32-8
6. Sandler B, Kase NG. Normal and abnormal menstruation. In: Kase NG, Weingold AB, Gershenson DM, editors. Principles and practise of clinical gynecology. 2nd ed. New York: Churchill Livingstone, 1990: 151-62
7. Cowan BD, Morrison JC. Management of abnormal genital bleeding in girls and women. N Engl J Med 1991; 324: 1710-5
8. Samsioe G. Bleeding problems in middle aged women. Maturitas 2002; 43 Suppl. 1: S27-33
9. Oldenhave A, Netelenbos C. Pathogenesis of climacteric complaints: ready for the change? Lancet 1994; 343: 649-53
10. Oldenhave A, Jaszmann LJ, Haspels AA, et al. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993; 168: 772-80
11. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25-31
12. Schneider HP. The quality of life in the post-menopausal woman. Best Pract Res Clin Obstet Gynaecol 2002; 16: 395-409
13. Brincat M, Moniz CJ, Studd JW, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985; 92: 256-9
14. Cummings SR, Kelsey JL, Nevitt MC, et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7: 178-208
15. Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992; 13 Suppl. 12: S1-10
16. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339: 733-8
17. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S-7S
18. Browner WS, Pressman AR, Nevitt MC, et al. Mortality following fractures in older women: the study of osteoporotic fractures. Arch Intern Med 1996; 156: 1521-5
19. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247-56
20. Thom TJ, Kannel WB, Siberhshatz H, et al. Incidence, prevalence, and mortality of cardiovascular disease in the United States. In: Alexander RW, Schlant RC, Fuster V, editors. New York: McGraw-Hill, 1997: 3-17
21. Gordon T, Kannel WB, Hortland MC, et al. Menopause and coronary heart disease. Ann Intern Med 1978; 89: 157-61
22. Smolders RGV, van der Mooren MJ. New emerging risk factors for cardiovascular disease. J Br Menopause Soc 2000; 6: 27-33
23. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 89-92
24. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388-95
25. Messinger-Rapport BJ, Sprecher D. Prevention of cardiovascular diseases: coronary artery disease, congestive heart failure, and stroke. Clin Geriatr Med 2002; 18: 463-83
26. Rowe JW, Kahn RL. Successful ageing. Gerontologist 1997; 37: 433-40
27. Harvey PD, Dahlman KL. Neuropsychological evaluation of dementia. In: Chalev A, editor. Neuropsychological assessment of neuropsychological disorders. Washington, DC: American Psychiatric Press, 1999: 329-77
28. Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive function with age: the Rancho Bernardo Study. J Am Geriatr Soc 1999; 47: 159-64
29. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988; 13: 345-57
30. Sherwin BB, Philips S. Estrogen and cognitive functioning in surgically menopausal women. Ann N Y Acad Sci 1990; 592: 474-5
31. Philips S, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992; 17: 485-95
32. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998; 50: 368-73
33. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-8
34. Hubert HB, Feinleib M, McNamara P, et al. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 768-77
35. National Task Force on the Prevention and Treatment of Obesity. Long term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-15
36. Brincat M, Moniz CF, Kabalan S, et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol 1987; 94: 126-9
37. Brincat MP. Hormone replacement therapy and the skin. Maturitas 2000; 35: 107-17
38. Bolger EO. Commencement and maintenance compliance of patients on hormone replacement therapy (HRT) following bilateral oophorectomy. J Obstet Gynaecol 2001; 21: 173-4
39. Campbell S, Whitehead M. Oestrogen therapy and the postmenopausal syndrome. Clin Obstet Gynecol 1977; 4: 31-47
40. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2001: CD002978
41. Kenemans P, van Unnik GA, Mijatovic V, et al. Perspectives in hormone replacement therapy. Maturitas 2001; 38 Suppl. 1: S41-8
42. Genazzani AR, Gambacciani M. HRT in the third millennium. Maturitas 2001 Jun 15; 38 Suppl. 1: S49-55
43. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of over-active bladder. Urology 2002; 60 (5 Suppl. 1): 64-71
44. Rice VM. Optimizing the dose of hormone replacement therapy. Int J Fertil Womens Med 2002; 47: 205-10
45. Ulrich LG, Barlow DH, Sturdee DW, et al. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. UK Continuous Combined HRT Study Investigators. Int J Gynaecol Obstet 1997; 59 Suppl. 1: S11-7
46. Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med 2000; 9: 381-7
47. Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001; 4: 314-9
48. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of lowdose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003; 44: 157-63
49. Hays J, Ockene JK, Brunner R, et al., for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-54
50. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2909-10
51. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
52. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1986; 6: 57-63
53. Haarbo J, Leth-Espersen P, Stender S, et al. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991; 87: 1274-9
54. Stevenson JC, Crook D, Godsland IF, et al. Hormone replacement therapy and the cardiovascular system: nonlipid effects. Drugs 1994; 47 Suppl. 2: 35-41
55. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995; 15: 827-36
56. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208
57. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-75
58. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72
59. Grodstein F, Stampfer MJ. Estrogen for women at varying risk of coronary disease. Maturitas 1998; 30: 19-26
60. Grodstein F, Manson JE, Colditz GA, et al. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-41
61. Mijatovic V, van der Mooren MJ. Menopause, oestrogens, SERM's and cardiovascular health in women. Eur J Obstet Gynecol Reprod Biol 2000; 93: 5-7
62. Van Baal WM, Kooistra T, Stehouwer CD. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women. Curr Med Chem 2000; 7: 499-517
63. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13
64. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9
65. Angerer P, Störk S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomised, controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 262-8
66. Hulley S, Furberg C, Barret-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58-66
67. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002; 109: 1056-62
68. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. WHI Investigators: effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-84
69. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-8
70. Clarckson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil Womens Med 2002; 47: 61-8
71. Van der Mooren MJ, Kenemans P. Postmenopausal hormone replacement therapy in the light of the Women's Health Initiative Trial. Eur J Obstet Gynecol Reprod Biol 2003; 107: 123-4
72. Genazzani AR, Gambacciam M, van der Mooren MJ, et al. Critical comments. Maturitas 2003; 44: 11-8
73. Toren-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992; 89: 4668-72
74. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994; 14: 459-71
75. Shumaker SA, Legault C, Thal L, et al., for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-62
76. Rapp SR, Espeland MA, Shumaker SA. et al., for the WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2663-72
77. Zandi PP, Breitner JC. Estrogen replacement and risk of Alzheimer disease. JAMA 2003; 289: 1100-2
78. Spencer CP, Godsland IF, Copper AJ, et al. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000; 49: 742-7
79. O'Sullivan AJ, Ho KK. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1783-8
80. Araujo DA, Farias MLF, Andrade ATL. Effects of transdermal and oral estrogen replacement therapy on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus. Climacteric 2002; 5: 286-92
81. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 128: 705-12
82. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-82
83. Nanda K, Bastian LA, Hasselblad V, et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-8
84. Smirnoff P, Liel Y, Gnainsky J, et al. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999; 11: 255-64
85. Fiorelli G, Picariello L, Martineti V, et al. Estrogen metabolism in human colorectal cancer cells. J Steroid Biochem Mol Biol 2002; 81: 281-9
86. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 2001; 40: 195-201
87. Montgomery Rice V. Hormone replacement therapy: optimising the dose and route of administration. Drugs Aging 2002; 19: 807-18
88. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995; 85: 304-13
89. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001; 8: 245-51
90. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003; 10: 113-32
91. Boerrigter PJ, van de Weijer PH, Baak JP, et al. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas 1996; 24: 63-71
92. Cerin A, Heldaas K, Moeller B. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy: the Scandinavian LongCycle Study Group. N Engl J Med 1996; 334: 668-9
93. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969-73
94. Dören M. Hormonal replacement regimens and bleeding. Maturitas 2000; 34 Suppl. 1: S17-23
95. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 1456-61
96. Naftolin F, Silver D. Is progestogen supplementation of ERT really necessary? Menopause 2002; 9: 1-2
97. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6-15
98. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80
99. Scarabin P-Y, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32
100. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-21
101. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59
102. Scheele F, Burger CW, Kenemans P. Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer. Maturitas 1999; 33: 191-6
103. Verheul HA, Coelingh-Bennink HJ, Kenemans P, et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000; 36: 1-17
104. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27
105. Speroff L. The Million Women Study and breast cancer. Maturitas 2003; 46: 1-6
106. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 1460-5
107. Hernandez E. Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 2001; 285: 3089-90
108. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2001; 135: 493-501
109. Uhler ML, Marks JW, Voigt BJ, et al. Comparison of the impact of transdermal venus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J Clin Endocrinol Metab 1998; 83: 410-4
110. Hemminki E, Brambilla DJ, McKinlay SM, et al. Use of estrogens among middle-aged Massachusetts women. DICP 1991; 25: 418-23
111. Topo P, Koster A, Holte A, et al. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. Maturitas 1995; 22: 89-95
112. Groeneveld FP, Bareman FP, Barentsen R, et al. Duration of hormonal replacement therapy in general practice: a follow-up study. Maturitas 1998; 29: 125-31
113. Pitkin J. Compliance with estrogen replacement therapy: current issues. Climacteric 2002; 5 Suppl. 2: 12-9
114. Sturdee DW. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int J Clin Pract 1999; 53: 468-72
115. De Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids 2000; 65: 671-9
116. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065-79
117. Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000; 11: 177-87
118. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361-76
119. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-5
120. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001; 76: 231-8
121. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87: 16-23
122. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002; 109: 886-93
123. Davis SR. The effects of tibolone on mood and libido. Menopause 2002; 9: 162-70
124. Kloosterboer HJ, Ederveen AGH. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (progestogen) treatments. J Steroid Biochem Mol Biol 2003; 83: 157-65
125. Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990; 76: 573-8
126. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059-63
127. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578-83
128. Van de Weijer P, Barentsen R. Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002; 42: 187-93
129. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-26
130. Barrett-Connor E. Raloxifene: risks and benefits. Ann N Y Acad Sci 2001; 949: 295-303
131. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: multiple outcomes of ratoxifene evaluation. JAMA 1999; 281: 2189-97
132. Barrett-Connor E, Grady D, Sashegyi A, et al., for the MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57
133. Harris ST. Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate. Osteoporos Int 2001; 12 Suppl. 3: S11-6
134. Cobin RH. AACE medical guidelines for clinical practice for management of menopause. Endocr Pract 1999; 5: 354-66
135. National Institutes of Health (NIH). Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17:1. Bethesda (MD): NIH, 2000: 1-45
136. Hodgson SF, Watts NB, Bilezikian JP, et al., for the American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001; 7: 293-312
137. Mosca L, Collins P, Herrington DM, et al., for the American Heart Association. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499-303
138. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003; 326: 322-6